Feedback / Questions
liraglutide subcutaneous prolonged-release (NEX-22) - Nanexa AB
https://nanexa.com/en/mfn_news/nanexa-doses-first-patient-in-the-30-mg-dose-group-in-the-phase-i-study-with-nex-22/
Mar 12, 2025
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Next